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A B S T R A C T
Background: Identifying patients with heart failure (HF) who are at risk of experiencing
symptomatic adverse drug events (ADEs) is important for improving patient care and
quality of life. Several demographic and clinical variables have been identiﬁed as potential
risk factors for ADEs but limited knowledge is available on the impact of HF patients’
beliefs and perceptions on their experience of ADEs.
Objective: The purpose of the study was to identify the relationship between HF patients’
illness perception and medication beliefs and self-reported ADEs.
Design: A cross-sectional survey was performed between November 2008 and March 2009.
Settings: One university medical centre, two regional hospitals and 20 general
practitioners in the Netherlands participated in the study.
Participants: 495 patients with HF were included.
Methods: Patients completed the validated Revised Illness Perception Questionnaire (IPQ-
R) and the Beliefs about Medication Questionnaire (BMQ) which collected data on their
illness perception and medication beliefs. In addition, data on ADEs as experienced in the
previous four weeks were collected through an open-ended question and a symptom
checklist. Multivariate logistic regression was performed to identify factors associated
with these ADEs.
Results: In total, 332 (67%) patients had experienced ADEs in the previous four weeks, of
whom 28% reported dry mouth, 27% dizziness and 19% itchiness as the most prevalent. In
the adjusted multivariate analysis, disease-related symptoms (illness identity) (OR for 1–5
symptoms 3.57; 95% CI 2.22–5.75, OR for >5 symptoms 7.37; 95% CI 3.44–15.8), and
general beliefs about medication overuse (OR 1.07; 95% CI 1.01–1.13) were independently
associated with experiencing ADEs, whereas none of the demographic or clinical factors
were signiﬁcant.
Conclusions: HF patients who perceive a high number of disease symptoms and have
negative medication beliefs are at higher risk of experiencing self-reported ADEs. We suggest
that future studies and interventions to improve ADE management should focus on negative
medication beliefs and assisting patients in differentiating disease symptoms from ADEs.
 2011 Published by Elsevier Ltd.
 Corresponding author at: University Medical Center Groningen, Sector F, Clinical Pharmacology, FB 20, 9713 AW Groningen, The Netherlands.
l.: +31 50 3632820; fax: +31 50 3632812.
E-mail address: p.denig@med.umcg.nl (Ruth H.E. De Smedt).
Contents lists available at ScienceDirect
International Journal of Nursing Studies
journal homepage: www.elsevier.com/ijns20-7489/$ – see front matter  2011 Published by Elsevier Ltd.
i:10.1016/j.ijnurstu.2011.05.014



1
a
m
r
e
d
o
m
m
(A
a
n
p
a
L
s
it
r
fr
p
m
n
c
a
s
u
a
a
e
2
9
d
r
a
a
R.H.E. De Smedt et al. / International Journal of Nursing Studies 48 (2011) 1540–1550 1541What is already known about the topic?
 Patients with HF experience a number of ADEs, such as
dizziness and nausea, which add to the disease burden
and affect patients’ medication adherence and quality of
life.
 Although older age, multimorbidity and polypharmacy
are potential risk factors for ADEs as documented in
medical records, demographic and clinical factors seem
to have a limited ability to predict self-reported ADEs
experienced by HF patients.
What this paper adds
 After controlling for demographic and clinical factors, the
reporting of more disease-related symptoms and stron-
ger general beliefs about medication overuse are
associated with experiencing ADEs.
 Future studies and interventions to improve ADE
management in HF should focus on negative medication
beliefs and assisting patients to differentiate ADEs from
disease symptoms.
. Introduction
Heart failure (HF) is a life-threatening health condition
ffecting approximately 15 million people in Europe and 5
illion people in the United States, with a prevalence
anging from 2% to 20% in patients aged over 65 (Dickstein
t al., 2008; American Heart Association, 2009). The
isease management of HF is complex, often consisting
f lifestyle modiﬁcation and lifelong therapy with multiple
edications. Alongside a reduction in mortality and
orbidity, medications can also cause adverse drug events
DEs), especially in elderly HF patients due to age-
ssociated changes in pharmacokinetics and pharmacody-
amics (Routledge et al., 2004; Shi et al., 2008). The
roportion of HF patients reporting ADEs varies from 10%,
ssessed in randomized clinical trials (Kostis et al., 1994;
akhdar et al., 2008), to 17%, found in an observational
tudy (De Smedt et al., 2009). The size of this problem and
s potential impact on actual medication use indicates the
elevance of ﬁnding better ways to manage ADEs, not only
om a clinical perspective but also from the patient’s
erspective.
In daily life, HF patients balance the need for prescribed
edication against any perceived ADE, which may lead to
on-adherence or permanent discontinuation of use of
ardiac medications (Garavalia et al., 2009; van der Wal
nd Jaarsma, 2008; van der Wal et al., 2010). This
uboptimal drug use is associated with an increase in
nplanned hospital admissions due to HF decompensation,
nd with increased mortality and morbidity rates,
ccompanied by additional health-care costs (Michalsen
t al., 1998; Gehi et al., 2007; Ho et al., 2008; Hope et al.,
004). Medication adherence rates in HF range from 75% to
9% (Muzzarelli et al., 2010; van der Wal et al., 2006),
epending on the method used to assess it (e.g. self-
eported questionnaires, pill counts, electronic monitoring
nd serum drug concentration) and the deﬁnition of non-
dherence (e.g. cut-off value of adherent behaviour versus
poor adherent behaviour). In addition to being a precipi-
tating factor leading to non-adherence, ADEs as perceived
by patients also contribute signiﬁcantly to the disease
burden and a decline in patients’ quality of life (Pattenden
et al., 2007; Welstand et al., 2009). Thus, from both a
clinical and patient perspective there is a need to prevent
and detect patient-perceived ADEs at an early stage of
routine care, which may lead to enhanced medication
safety and wellbeing among HF patients.
Management of ADEs in HF patients appears subopti-
mal. Recent data has indicated that the likelihood of
medication being changed after patients report ADEs is
rather low, at around 38% (De Smedt et al., 2010). The
failure to respond to medication-related symptoms may
lead to unnecessary harm caused by ADEs, which could
have been prevented or ameliorated if adequate action had
been taken (Forster et al., 2005; Gandhi et al., 2003).
Polypharmacy, multicomorbidity, ageing and the involve-
ment of multiple health-care providers are factors
contributing to the complexity of ADE management in
HF patients. Nurses and nurse practitioners are increas-
ingly involved in the supervision of drug use and drug
treatment changes in HF patients (Blue and McMurray,
2005). Therefore they have an important role in patient
education about possible ADEs, ADE identiﬁcation and
consequently the management of ADEs.
Health-care providers and researchers have a growing
interest in reducing the occurrence of ADEs and improving
their management in routine care. It has been suggested
that identifying patients who are at higher risk is crucial to
improving patient care and outcomes (Tangiisuran et al.,
2009). Higher age, the number of comorbidities and
number of medications have been shown to be risk factors
for ADEs in various populations (Field et al., 2004; Green
et al., 2007; van den Bemt et al., 2000). These studies
investigated risk factors for ADEs that were documented
and/or veriﬁed by medical-record review or computer-
generated signals. It is recognized that self-reported ADEs
are of additional value as they incorporate patient
experiences and may be more important for daily health
status than clinician assessments of ADEs (Hanlon et al.,
2001; Basch et al., 2009). A few studies have attempted to
identify factors associated with self-reported ADEs,
demonstrating that demographic and clinical variables
such as age and comorbidities have a low ability to predict
the risk of self-reported ADEs in HF patients and elderly
patients in general (De Smedt et al., 2009; Shiyanbola and
Farris, 2010). Other factors such as patients’ beliefs about
medication and illness can be expected to play a role in
how patients perceive and deal with possible ADEs.
Optimistic attitudes regarding drugs and fewer concerns
about medication were found to be associated with less
experience and reporting of ADEs in a general patient
population (Shiyanbola and Farris, 2010; Oladimeji et al.,
2008; Rief et al., 2006). The importance of illness
perception has been demonstrated with respect to various
outcomes, such as quality of life (Lane et al., 2009; Stafford
et al., 2009), depression (Stafford et al., 2009) and
treatment adherence (Molloy et al., 2009). However, thus
far the role of illness and medication beliefs in the
susceptibility of HF patients to perceive ADEs is not
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 achieved by identifying such patient-related factors.
is can assist health-care professionals in the complex
ocess of ADE management. If the type or number of
edications is not the main risk factor for ADEs as
perienced by HF patients, interventions other than
edication modiﬁcation need to be considered.
 Purpose
The aim of this study is to assess the inﬂuence of illness
rception and medication beliefs on self-reported ADEs
perienced by HF patients.
 Methods
. Study design
A cross-sectional survey was conducted between
vember 2008 and March 2009. The study protocol
d procedures were presented for approval to the Medical
hics Committee at the University Medical Center of
oningen. Due to the nature of the study (survey and
edical-record review), the ethics committee concluded
at no ofﬁcial ethical approval was required to perform
e study. The investigation also conforms to the principles
tlined in the Declaration of Helsinki (1997).
. Setting, patients and procedure
All ambulatory HF patients were recruited from one
iversity hospital (urban area), two regional hospitals
ral areas) and 20 general practitioners (urban and rural
eas) located in different parts of the Netherlands. The
clusion of institutions was based on geographical
presentation, including both urban and rural areas, the
ailability of an HF clinic and a willingness to collaborate.
All HF patients from outpatient HF clinics were eligible if
ey had a documented diagnosis of HF in their medical
art. All HF patients from the 20 general practitioners were
entiﬁed by the International Classiﬁcation of Primary Care
de for heart failure (K77) found in their medical record and
ere included if their general practitioner conﬁrmed this
agnosis. The exclusion criteria were living in a nursing
me, being hospitalized, not being ﬂuent in Dutch, or
ving a terminal disease or cognitive disorder.
An information letter was sent to all eligible patients by
e researchers explaining the purpose of the study and
questing their participation. Permission to send a
estionnaire and conduct a review of their medical
cord was also asked of the patient. A reminder was sent
 those patients who had not responded one month after
e ﬁrst letter. After signing the informed consent, patients
ere asked to indicate on the same form whether they had
perienced an adverse event of their medication in the
evious four weeks.
. ADE assessment
The outcome measure was any ADE experienced by
tients in the previous four weeks. This short time frame
was chosen to reduce the risk of recall bias in light of the
rather mild ADEs. Information on perceived ADEs was
collected using a mixed method, combining an open-ended
question and a symptom checklist. Various studies suggest
that the mixed method is a preferred way of eliciting ADEs,
as patients do not report all ADEs in response to a single
open question (Sheftell et al., 2004; Wallander et al., 1991).
On the informed consent form patients were asked ﬁrst
to answer the following question: ‘Have you experienced
an adverse event with your medication in the past four
weeks?’ (Yes/No) If Yes, patients were then asked through
an open-ended question to list the ADEs they had
experienced in the previous four weeks. After receiving
this information and the signed informed consent, a
structured questionnaire with a checklist including 28
symptoms was sent to the patients. Patients could
complete the questionnaire themselves or – on a patient’s
request – with the assistance of a data collector who was
not a member of the research team.
The symptom checklist is presented in Fig. 1. The
inclusion of symptoms in this list was partly based on a
previous study which not only assessed common symp-
tomatic ADEs in HF patients (De Smedt et al., 2009) and
commonly perceived symptoms in HF were also included.
Patients were ﬁrst asked whether they had experienced
each of the symptoms in the previous four weeks, and
second, whether they attributed the symptom to an
adverse event of their medication and/or to HF. The
deﬁnition of ADEs experienced by HF patients used in this
study includes all ADEs reported on the open-ended
question plus the symptoms reported on the checklist that
were exclusively considered by the patient to be an
adverse event of their medication.
3.4. Measures
Illness perception: Illness perception was measured
using the Revised Illness Perception Questionnaire (IPQ-R)
(Moss-Morris et al., 2002). The IPQ-R is a valid and reliable
measure of illness perception in chronic diseases such as
cardiac disease, including patients with myocardial
infarction (Moss-Morris et al., 2002). The ﬁrst domain of
the IPQ-R is the illness identity scale, which consists of the
symptom checklist mentioned above. The score of this
scale was the sum of all symptoms exclusively attributed
by patients to their HF, according to the concept of illness
identity (Moss-Morris et al., 2002), ranging from 0 to 28.
The other seven domains of the IPQ-R included in the
questionnaire were: chronic timeline (e.g. ‘My HF is rather
permanent than temporary’), cyclical timeline (e.g. ‘The
symptoms of my HF change a great deal from day to day’),
consequences (e.g. ‘My HF has major consequences for my
life’), personal control (e.g. ‘There is a lot which I can do to
control my symptoms’), treatment control (e.g. ‘My
treatment can control my HF’), illness understanding
(e.g. ‘The symptoms of my HF are puzzling to me’) and
emotional representations (e.g. ‘My HF makes me feel
afraid’). Each subscale consisted of 4–6 items and a score
was calculated for each of these subscales, where a higher
score represented greater endorsement of the speciﬁc
construct. We checked the internal reliability of the seven
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oth control subscales (personal and treatment), all
ronbach’s alpha coefﬁcients exceeded 0.70. Other studies
ave also found alpha coefﬁcients for the personal (0.69)
nd treatment control scales (0.59) to be low (Aalto et al.,
005; Molloy et al., 2009). The response scale for all items
onsisted of a 5-point Likert scale ranging from 1 (‘strongly
isagree’) to 5 (‘strongly agree’). For the multivariate
nalysis, the IPQ-R subscales were categorized in 3 classes
 = low, M = medium, H = high). Scale-categorization was
eﬁned as: 4–8 (L), 9–15 (M), 16–20 (H); 5–11 (L), 12–18
), 19–25 (H); 6–13 (L), 14–22 (M), and 23–30 (H). Illness
entity was categorized in 0 (L), 1–5 (M), and >5 (H)
ymptoms.
Medication beliefs: Medication beliefs were assessed
sing the Beliefs about Medication Questionnaire (BMQ)
orne et al., 1999). The BMQ is a validated and reliable
uestionnaire that includes 18 items assessing patients’
iews on HF medication-related concerns (a = 0.73) and on
their views on general medication overuse (a = 0.67) and
medication-related harm (a = 0.57). The response scale for
all items is a 5-point Likert scale ranging from strongly
disagree (1) to strongly agree (5). For the multivariate
analysis, subscales were categorized in 3 classes (L = low,
M = medium, H = high). Scale-categorization for BMQ
subscales included: 4–8 (L), 9–15 (M), 16–20 (H); 5–11
(L), 12–18 (M), and 19–25 (H).
Demographic and clinical variables: Data on age, gender,
living situation (living alone or not) and educational level
(no education, primary school, secondary school, higher
education/university) were collected by self-reported
questionnaire. Data on all medication currently used
(name of the drug, dosage and frequency) was also
collected by the questionnaire. The following data were
collected by medical-record review: aetiology and dura-
tion of HF (years), left ventricular ejection fraction (LVEF)
(%), N-terminal pro-‘Brain Natriuretic Peptide’ (NT-pro-
BNP) (pg/ml) and comorbidities, which are prevalent in HF
This symptom is an adverse This symptom is due Did you experience this Symptoms 
symptom in the previous 4 
weeks event of my medication to my heart failure 
Yes No 
Nausea 1. 
Dizziness 2. 
Gout 3. 
Dyspnoea 4. 
Swollen ankels 5. 
Vomiting 6. 
Diarrhea 7. 
Dry cough 8. 
Cough 9. 
Erectile dysfunction 10. 
Libido loss 11. 
Fatigue 12. 
Sleeping problems 13. 
Cold extremities 14. 
Headache 15. 
Stomach problems 16. 
Painful joints 17. 
Decrease in bodyweight 18. 
Increase in bodyweight 19. 
Fluid retention 20. 
Loss of appetite 21. 
Painful breasts 22. 
Dry mouth 23. 
Blurred vision 24. 
Hair loss 25. 
Skin rash 26. 
Itchiness 27. 
Constipation  28. 
Fig. 1. Symptom checklist.atients.e necessity of their HF medication (a = 0.83), as well as p
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Descriptive analysis of demographic, clinical and
ychosocial variables was undertaken using the mean
d the standard deviation for normally distributed
ntinuous variables or the median with interquartile
nges (IQR) in the case of data skewness. Summary
atistics were calculated for all participants together and
r the two subgroups separately, deﬁned as patients who
perienced an ADE and patients who did not. Differences
ere tested using a Chi2 test for categorical variables and
dependent t-tests for continuous variables or Mann–
hitney U and Welch U tests in case of skewed
stributions or unequal variances (Fagerland and Sand-
k, 2009). Bonferroni post hoc test was used to correct for
ultiple testing. To assess whether patients from general
actitioners differed from patients from HF outpatient
nics regarding the reported ADEs and both illness and
edication beliefs, we tested for differences using Chi2
sts, t-tests or Mann–Whitney U tests. A multivariate
gistic regression was performed to evaluate the factors
dependently associated with experiencing ADEs. We
ed a stepwise selection procedure, including ﬁrst those
riables with a p-value of 0.20 or less in the univariate
alysis for a forward model selection. Next, variables
ith a p-value of 0.20 or less in the forward selection
gression model were included in the unadjusted
ultivariate model. The ﬁnal model was adjusted for
nfounders, which were expected to be associated with
periencing ADEs and correlated with at least one of the
bscales of illness perception (IPQ-R) or medication
liefs (BMQ). These were age, recent hospitalization,
ated by a cardiologist (as proxy for more complicated
ses), use of potassium-sparing diuretics, and use of
ticoagulants. Missing values for these confounders
ere lower than 10%, and they were therefore imputed
ing multiple imputation by chained equations (van
uren et al., 1999). We conducted an additional
ultilevel analysis to test for cluster effects at practice
ganization level, i.e. general practice or hospital
tpatient clinic. The results are presented using odds
tios, with a 95% conﬁdence interval (CI). Descriptive and
mparative analyses were conducted using SPSS 16.0
ftware (SPSS, Inc., Chicago, IL, USA.), whereas all
gression analyses and multiple imputations were
nducted using Stata 11 (StataCorp LP, College Station,
, USA).
 Results
Of the 960 HF patients who were invited to participate
 the study, 495 (response rate: 53%) patients agreed and
ned the informed consent form. Of these 495 patients,
4 (23%) were recruited through their general practition-
 and the remaining 381 (77%) through HF outpatient
nics. The mean age of the study sample was 71 years (SD,
 years) (Table 1). The majority were male (60%), did not
e alone (63%) and had a secondary school level of
ucation (58%). The median LVEF was 35% (IQR, 26–45)
d on average the patients took 7 (IQR, 5–9) different
pes of drugs a day.
Of the 495 patients, 67% (n = 332) had experienced an
ADE in the previous four weeks. Of these, 81 (24%) reported
an ADE on the open-ended question and symptom checklist,
while the remaining 251 (76%) only reported an ADE on the
symptom checklist. A total number of 1341 ADEs (4.0 per
patient) were reported, of which 164 ADEs were noted in
response to the open-ended question while the remaining
1177 ADEs were reported via the symptom checklist. Of all
patients experiencing an ADE, 28% reported dry mouth, 27%
dizziness and 19% itchiness as the most prevalent. Patients
who experienced an ADE were somewhat younger
(p = 0.023), used more medications (p = 0.001), more often
took anticoagulants (p = 0.013) and potassium-sparing
diuretics (p = 0.010) and were more likely to have been
hospitalized in the previous year (p = 0.024) compared to
patients who did not experienced an ADE (Table 1).
When comparing HF patients treated by their general
practitioner with those treated at HF outpatient clinics, the
proportion of patients experiencing ADEs was not signiﬁ-
cantly different (65% and 68% respectively, p = 0.632).
4.1. Perceived symptoms attributed to HF (illness identity) or
to medication (ADEs)
The total group of 495 patients reported 1486
symptoms (3.0 per patient) on the checklist which they
attributed solely to their illness, and another 1177
symptoms (2.4 per patient) which they attributed solely
to their medication (Fig. 2). Those who experienced an ADE
reported signiﬁcantly more symptoms (9.8 per patient)
compared to patients with no ADE (5.7 per patient), and
consequently attributed more symptoms to their illness
(3.6 symptoms per patient versus 1.7 symptoms per
patient) (both p < 0.001). This previous measure reﬂects
the patient’s illness identity. In addition, the patients
reported 1393 symptoms that they did not attribute to
either their illness or their medication, and this was higher
for the patients without an ADE than for those patients
who experienced an ADE (4.0 per patient versus 2.2 per
patient, p < 0.001). Finally, 122 symptoms were attributed
by patients experiencing ADEs to both the illness and the
medication (Fig. 2).
4.2. Illness perception and medication beliefs
Patients who experienced an ADE reported signiﬁcantly
more of the following disease-related symptoms in
comparison to patients without an ADE (for all p-value
<0.002): dyspnoea, fatigue, cold extremities, ﬂuid reten-
tion, swollen ankles, and cough (Table 2).
In general, patients with an ADE had more negative
beliefs about their illness and medication than patients
without an ADE. They perceived their illness as more
unstable, perceived more consequences for their daily life,
and suffered more emotional distress (for all, p < 0.005).
They also had more concerns about their medication, and
had a greater belief in medication overuse (for both,
p < 0.005).
When comparing HF patients treated by their general
practitioner with those treated at HF outpatient clinics, the
latter perceived more consequences of their HF (p = 0.008)
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eneral practitioners (p = 0.004).
.3. Multivariate model
Based on the univariate selection, HF identity, timeline
yclical, consequences, emotional representation, medica-
on necessity, medication concerns, general medication
arm and overuse were included in the forward model
election (Table 3). Of these, illness identity, consequences,
ersonal control, medication concerns and overuse were
elected for the multivariate model. Looking at the
nadjusted model, experiencing an ADE was signiﬁcantly
elated to the reporting of more disease-related symptoms
trong illness identity) (OR for 1–5 symptoms 3.64 [95% CI
.29–5.79]; OR for >5 symptoms 6.69 [95% CI 3.17–14.10])
nd stronger beliefs regarding general medication overuse
R 1.82 [95% CI 1.12–2.94]). After adjusting the model for
confounders, both factors were still independently associ-
ated with experiencing ADEs (Table 3). The demographic
and clinical variables used for adjustment were not
signiﬁcant independent risk factors with respect to
experiencing ADEs in the multivariate model (age OR
0.99 [95% CI 0.97–1.01], anticoagulants OR 1.24 [95% CI
0.79–1.94], potassium-sparing diuretics OR 1.44 [95% CI
0.91–2.29], hospitalization in the previous year OR 1.27
[95% CI 0.81–1.98], treated by cardiologist OR 0.93 [95% CI
0.43–2.01]). In the multilevel model, no evidence was
found for clustering at practice organization level.
5. Discussion
The major ﬁnding of this study is that general illness
and medication beliefs were associated with self-reported
ADEs, which were commonly experienced in this HF
patient population. After adjusting for demographic and
able 1
emographic and clinical characteristics of all patients and of patients with and without perceived ADEs.
Characteristic Total (n = 495) ADE perceived
(n = 332)
No ADE perceived
(n = 163)
p-Value
Demographics
Age (years) 71  12 70  12 73  13 0.023
Female 198 (40) 125 (38) 73 (45) 0.128
Education 275 (58) 190 (60) 85 (55) 0.243
No education/primary school 100 (21) 67 (21) 33 (21) 0.689
Secondary school 277 (59) 182 (58) 95 (61)
Higher education/university 95 (20) 67 (21) 28 (18)
Living alone 175 (37) 112 (35) 63 (39) 0.361
Receiving care at home 194 (41) 123 (39) 71 (46) 0.146
Clinical characteristics
Duration of heart failure (years)* 3 (2–5) 3 (2–5) 3 (2–5) 0.648y
LVEF (%)* 35 (26–45) 35 (26–46) 35 (25–46) 0.628y
NT-proBNP (pg/ml)* 1054 (411–2352) 1093 (380–2341) 998 (508–2352) 0.987y
Ischemic etiology of HF 249 (51) 177 (54) 72 (45) 0.051
Comorbidities
Peripheral vascular disorders 104 (21) 71 (22) 33 (21) 0.770
Respiratory disorders (COPD/asthma) 136 (28) 93 (28) 43 (27) 0.703
Diabetes type II 112 (23) 75 (23) 37 (23) 0.977
Renal disorders 79 (16) 52 (16) 27 (17) 0.796
Depression (diagnosis) 41 (8) 31 (10) 10 (6) 0.218
Total number of prescribed medications 7.6 (0.2) 7.9 (0.2) 6.8 (0.3) 0.001#
Heart failure medication
ACE-inhibitors 302 (61) 206 (62) 96 (59) 0.499
Angiotensin receptor blockers 124 (25) 80 (24) 44 (27) 0.484
Beta-blockers 404 (82) 274 (83) 130 (80) 0.454
Diuretics
Loop diuretics 345 (70) 239 (72) 106 (65) 0.113
Potassium-sparing diuretics 179 (36) 133 (40) 46 (28) 0.010
Cardiac glycosides 50 (10) 33 (10) 17 (10) 0.865
Other medication
Calcium channel blockers 74 (15) 55 (17) 19 (12) 0.150
Nitrates 97 (20) 65 (20) 32 (20) 0.989
Lipid-lowering agents 234 (47) 160 (48) 74 (45) 0.558
Antiplatelet agents 163 (33) 108 (33) 55 (24) 0.787
Anticoagulants 270 (55) 194 (58) 76 (47) 0.013
Antiarrhythmic agents 52 (11) 39 (12) 13 (8) 0.198
Received care in the previous year
Under treatment of a cardiologist 451 (92) 305 (93) 146 (90) 0.192
Under treatment of a outpatient HF clinic 381 (77) 258 (78) 123 (75) 0.875
Hospitalization 211 (44) 153 (47) 58 (36) 0.024
DE, adverse drug event; LVEF, left ventricular ejection fraction; NT-pro BNP, N-terminal pro B-type natriuretic peptide; HF, heart failure; COPD, chronic
bstructive pulmonary disease; ACE-inhibitors, angiotensine converting enzyme inhibitors.
* Continuous variable is presented as median value (25–75th percentiles).
y Using non-parametric Mann–Whitney U test.
# Using Welch U test.
Fig. 2. Symptoms reported by patients and attributed to HF and/or to drugs. Note: The sum of symptoms solely attributed to HF is the illness identity. Normal
range 0–28.
Table 2
Identity subscale of the IPQ-R including 28 common symptoms of heart failure.
This complaint is due to my heart failure Total group
(n = 495)
n (%)
Experienced ADE
(n = 332)
n (%)
Experienced no
ADE (n = 163)
n (%)
p-Value
Dyspnoea 242 (49) 192 (58) 50 (31) 0.000*
Fatigue 227 (46) 177 (53) 50 (31) 0.000*
Cold extremities 164 (33) 126 (38) 38 (23) 0.001*
Fluid retention 130 (26) 110 (33) 20 (12) 0.000*
Swollen ankles 109 (22) 88 (27) 21 (13) 0.001*
Dry cough 71 (14) 56 (17) 15 (9) 0.022
Sleeping problems 70 (14) 56 (17) 14 (9) 0.013
Dizziness 61 (12) 50 (15) 11 (7) 0.008
Cough 49 (10) 43 (13) 6 (4) 0.001*
Increase in bodyweight 42 (9) 36 (11) 6 (4) 0.007
Dry mouth 40 (8) 28 (8) 12 (7) 0.681
Painful joints 35 (7) 29 (9) 6 (4) 0.039
Libido loss 32 (7) 27 (8) 5 (3) 0.031
Headache 32 (7) 27 (8) 5 (3) 0.031
Nausea 30 (6) 27 (8) 3 (2) 0.006
Erectile dysfunction 28 (6) 24 (7) 4 (3) 0.031
Loss of appetite 24 (5) 21 (6) 3 (2) 0.029
Blurred vision 23 (5) 21 (6) 2 (1) 0.011
Gout 16 (3) 14 (4) 2 (1) 0.077
Decrease in bodyweight 13 (3) 11 (3) 2 (1) 0.173
Painful breasts 12 (2) 11 (3) 1 (0.5) 0.066
Stomach problems 7 (1) 6 (2) 1 (0.5) 0.290
Diarrhea 7 (1) 6 (2) 1 (0.5) 0.290
Vomiting 7 (1) 7 (2) 0 0.062
Itchiness 7 (1) 4 (1) 3 (2) 0.573
Constipation 4 (1) 3 (1) 1 (0.5) 0.735
Skin rash 2 (0.5) 1 (0.5) 1 (0.5) 0.607
Hair loss 2 (0.5) 1 (0.5) 1 (0.5) 0.607
Total 1486 1202 284
ADE, adverse drug event; HF, heart failure.
* Variables with a signiﬁcance difference after applying the Bonferroni post hoc test p < 0.05/28 variables p < 0.002.
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elated symptoms and stronger general beliefs about
edication overuse were associated with experiencing
DEs. In the ﬁnal model, demographic and clinical
haracteristics were not independent risk factors for
elf-reported ADEs.
Patients who experienced more symptoms that were
ttributed to their HF (illness identity) were also more
kely to experience an ADE. The importance of illness
entity as a predictor of different outcomes in cardiac
isease has already been described in other studies (Aalto
t al., 2006; Lane et al., 2009; French et al., 2006). Our
tudy, however, is the ﬁrst to ﬁnd a relationship between
lness identity and the experience of ADEs. Several reasons
ight be given to explain this relationship. First, it is
ossible that patients who suffer from severe HF experi-
nce more disease-related symptoms. Increased symp-
ms may indicate the need to intensify drug treatment,
hich in turn may lead to an increased likelihood of drug-
elated symptoms (Gandhi et al., 2003). However, in this
tudy, both the medications used and LVEF and NT-pro-
NP (both markers of disease severity) were not found to
dependently predict ADE experiences, which challenge
is assumption. Moreover, we adjusted for differences in
peciﬁc medication use in the ﬁnal multivariate model.
aking into account the results of a previous study which
lso found no association between medication burden,
isease severity and the experience of ADEs, we presume
at the type of medication and disease severity do not
lay a major role as explanatory factors (De Smedt et al.,
2009). Second, patients’ lack of knowledge and their
inability to differentiate disease and drug-related symp-
toms might be a factor underlying the relationship
between an illness identity and experiencing ADEs. Earlier
studies have shown that HF patients have difﬁculties in
differentiating disease and drug-related symptoms (Rogers
et al., 2002). From our study results, it seems that this
problem was much more apparent in the group of patients
who did not report any ADEs, as the number of
unattributed symptoms was much higher in this group
compared to the group who did experience an ADE. This
indicates that the group of patients who do not report ADEs
may not have been able to clearly distinguish drug-related
symptoms from HF symptoms. Nurse practitioners could
play an important role in educating patients about possible
ADEs and helping them in differentiating ADEs from
disease symptoms (Roberts and Epstein, 2009). We did not
assess the underlying rationale of patients who did not
attribute the perceived symptom to HF or their medication.
It is possible that patients perceived other factors such as
age or comorbid diseases as causes. Elderly patients in
general tend to consider observed symptoms as unavoid-
able aspects of ageing rather than as disease or drug-
related (Lampela et al., 2007). A third and ﬁnal explanation
of the relationship between a strong illness identity and
experiencing ADEs could be that some patients are more
prone to perceive both somatic symptoms and ADEs
(somatic sensitivity). Personality characteristics such as
neuroticism, which is the tendency to experience negative,
distressing emotions, and type D personality have been
able 3
ssociation of illness and medication beliefs and perceiving an ADE (0 = no ADE perceived, 1 = ADE perceived).
Factors Univariate Multivariate unadjusted
(n = 485)
p-Value Multivariate adjusted*
(n = 485)
p-Value
p-Value Odds ratio 95% CI Odds ratio 95% CI
IPQ-R Identity HF 1–5 <0.001 3.64 2.29–5.79 <0.0001 3.50 2.18–5.63 <0.0001
Identity HF >5 <0.001 6.69 3.17–14.10 <0.0001 6.88 3.22–14.68 <0.0001
Timeline chronic M 0.656 – –
Timeline chronic H 0.538
Timeline cyclical <0.001 – –
Consequences <0.001 1.04 1.00–1.09 0.035 1.02 0.98–1.06 0.264
Personal control M 0.091 0.52 0.24–1.11 0.090 0.53 0.25–1.13 0.099
Personal control H 0.254 0.52 0.24–1.16 0.111 0.51 0.23–1.14 0.100
Treatment control M 0.369 – –
Treatment control H 0.537
Illness coherence M 0.838 – –
Illness coherence H 0.863
Emotional repres. M 0.039 – –
Emotional repres. H 0.008
BMQ Necessity M 0.350 – –
Necessity H 0.094
Concerns M 0.018 1.22 0.76–1.98 0.409 1.25 0.77–2.04 0.361
Concerns H 0.047 1.46 0.67–3.17 0.340 1.49 0.68–3.29 0.320
Harm M 0.061 –
Harm H 0.383
Overuse 0.001 1.82 1.12–2.94 0.015 1.07 1.01–1.13 0.022
Goodness-of-ﬁt statistics: area under ROC
curve 0.747; Hosmer–Lemeshow Chi2,
p = 0.44
Goodness-of-ﬁt statistics: area under ROC
curve 0.749; Hosmer–Lemeshow Chi2,
p > 0.47 (imputed models)
DE, adverse drug event; IPQ-R, Illness Perception Questionnaire Revised; BMQ, Beliefs about Medication Questionnaire; HF, heart failure; M, medium
ore; H, high score.
* Multivariate model adjusted for age, potassium sparing diuretics, anticoagulants, treated by a cardiologist, hospitalization in previous year.
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mptoms (Rosmalen et al., 2007; Smith et al., 2008).
Patients who had more concerns regarding their
edication and believed that medication in general is
erused were more likely to experience ADEs. This is in
e with an earlier study that found an association
tween patients’ medication concerns and their reporting
 ADEs to their physicians (Oladimeji et al., 2008). It was
ggested that patients’ beliefs about medication might
o be important with respect to how symptoms are
terpreted and attributed to drugs, which is supported by
r results and a recent study among elderly patients
hiyanbola and Farris, 2010). Patients who have stronger
gative beliefs may be more aware of unpleasant
actions and be more prejudiced towards their medica-
n. Patients’ concerns about medication may drive them
 attribute their symptoms to medication and may be a
n of their ADE tolerance level (Oladimeji et al., 2009).
r study suggests that general negative beliefs are a
onger risk factor than speciﬁc concerns about the
edication which is used. This emphasizes the relevance
 health-care providers checking patients’ interpretations
 symptoms, especially in those patients who have
gative medication beliefs.
Demographic and clinical variables were not inde-
ndent risk factors with respect to experiencing ADEs.
is is in accordance with previous studies which
amined risk factors associated with self-reported ADEs
ong general older populations (De Smedt et al., 2009;
nlon et al., 1997; Oladimeji et al., 2008; Shiyanbola
d Farris, 2010). However, studies using other methods
 identify ADEs, such as medical-record review, clinical
tes and computer-generated signals, found a number
 risk factors for ADEs in the elderly, such as the number
 comorbidities and scheduled medications (Field et al.,
04; Green et al., 2007; van den Bemt et al., 2000). This
ggests that demographic and clinical variables are
ore relevant for predicting the risk of clinically assessed
Es, while other factors such as medication beliefs and
tients’ susceptibility to perceive symptoms may be
ore relevant for predicting the risk of subjective ADEs.
is highlights the complex task of health-care providers
 elicit, identify and manage ADEs. Patients’ perceptions
e important not only in helping to identify possible
Es, but also in managing them. A patient-tailored
proach where nurse practitioners and doctors proac-
ely communicate with their patients about possible
Es might be valuable.
To our knowledge, this is the ﬁrst study to examine the
le of illness perception and medication beliefs in
periencing ADEs in a population of HF patients. Some
itations need to be addressed. This study relies on self-
ported data collected by a questionnaire using an open-
ded question combined with a symptom checklist to
entify ADEs experienced by patients. We did not link the
ported ADEs to actual drugs. No formal ADE causality
sessment was carried out because the study focused on
e perception of patients. Because of the cross-sectional
sign, no judgement about causality can be made.
other potential limitation of this study is its generaliz-
able to compare responders and non-responders to the
survey. Our study sample includes ambulatory patients
from outpatient clinics and general practices. Regarding
age and gender, this sample was largely comparable to
another Dutch outpatient clinic population screened
around 2002–2005 (mean age of 71 years in both study
populations; proportion of female patients 40% versus
38%) (Jaarsma et al., 2008). In comparison with a primary
care study population, the mean age was lower in our
population (71 years versus 76 years), and the proportion
of female patients less (40% versus 47%) (Bosch et al.,
2010). There are some differences regarding treatment,
which may in part be due to changes in prescribing
practices over recent years. The proportion of patients
treated with diuretics, angiotensin-converting enzyme
inhibitors (ACE-I) and beta-blockers was higher in
comparison to the primary care study population
screened in 2005–2006. In comparison with the outpa-
tient clinic study population, patients in our study sample
were prescribed more beta-blockers and fewer ACE-I.
Such differences in age, gender and treatment can lead to
differences in the number of ADEs experienced. One can
only speculate as to how this may affect the observed
associations between beliefs and the experience of ADEs.
We have found no literature supporting the notion that
such associations are likely to be affected by age or
gender.
6. Conclusion
In conclusion, this study indicates that HF patients who
experience a high number of disease-related symptoms
and have stronger general beliefs about medication
overuse are at a higher risk of experiencing self-reported
ADEs. Because of the high prevalence of such ADEs in this
group of patients there is a need for adequate manage-
ment. Future studies should focus on the role of personality
characteristics as well as on the mechanisms underlying
the observed associations. Nursing interventions could
focus on providing patients with tailored information on
possible ADEs, assisting them in differentiating disease
symptoms from ADEs, and detecting negative medication
beliefs.
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